---
output: fost::jlr_manuscript
---



# Supplemental Tables


| Model           | QIC     | Delta |
|:----------------|:--------|:------|
| **log(ISI)**    | NA      | NA    |
| M7              | -1610.5 | 0.0   |
| M8              | -1608.9 | 1.6   |
| M9              | -1607.9 | 2.6   |
| M5              | -1604.1 | 6.4   |
| M6              | -1602.4 | 8.1   |
| M4              | -1599.2 | 11.3  |
| M3              | -1575.6 | 34.8  |
| M1              | -1229.7 | 380.8 |
| M0              | -1228.2 | 382.3 |
| M2              | -1219.2 | 391.3 |
| **log(ISSI-2)** | NA      | NA    |
| M8              | -2476.2 | 0.0   |
| M9              | -2474.3 | 1.9   |
| M6              | -2471.3 | 4.9   |
| M7              | -2467.4 | 8.9   |
| M4              | -2458.8 | 17.4  |
| M5              | -2456.5 | 19.7  |
| M3              | -2450.5 | 25.7  |
| M2              | -2226.5 | 249.7 |
| M0              | -2171.0 | 305.2 |
| M1              | -2168.5 | 307.8 |

Table: Supplemental Table S  1: Comparison of GEE model fitness for variable selection using quasi-likelihood information criteria.

Given the number of possible combinations of outcome and predictor variables,
only ISI and ISSI-2 with total TGFA (nmol/mL) were used to
compare various GEE models and to select a final model.  Baseline age was used
as including both the original age and the time variable would result in
collinearity.  Column names: QIC is the quasi-likelihood information criteria
(smaller values, eg. larger negative values, indicate a better fit compared to
other models), Delta is the QIC minus the lowest QIC (models with delta <10 are 
considered equivalent).  Models were:

- M0: log(ISSI-2) or log(ISI) = total TGFA (nmol/mL) + years from baseline
- M1: M0 + fatty acid by time interaction
- M2: M0 + sex + ethnicity + baseline age
- M3: M2 + WC
- M4: M3 + ALT
- M5: M4 + physical activity (MET)
- M6: M5 + total NEFA
- M7: M6 + alcohol intake
- M8: M7 + family history of diabetes
- M9: M8 + smoking status


| TGFA     | Concentrations (nmol/mL) | Proportion (mol%) |
|:---------|:------------------------:|:-----------------:|
| 18:3 n-3 |       45.2 (31.1)        |     1.5 (0.6)     |
| 20:5 n-3 |        9.9 (8.1)         |     0.4 (0.4)     |
| 22:5 n-3 |        8.3 (5.7)         |     0.3 (0.2)     |
| 22:6 n-3 |       16.7 (14.5)        |     0.6 (0.6)     |
| 18:2 n-6 |      548.6 (298.7)       |    18.0 (4.2)     |
| 18:3 n-6 |        15.1 (9.9)        |     0.5 (0.2)     |
| 20:2 n-6 |        10.2 (4.7)        |     0.4 (0.1)     |
| 20:3 n-6 |        10.2 (6.0)        |     0.3 (0.1)     |
| 20:4 n-6 |       38.2 (19.1)        |     1.3 (0.5)     |
| 22:4 n-6 |        4.6 (2.9)         |     0.1 (0.1)     |
| 14:1 n-7 |        5.1 (6.1)         |     0.1 (0.1)     |
| 16:1 n-7 |       126.1 (98.8)       |     3.8 (1.3)     |
| 18:1 n-7 |       71.6 (34.8)        |     2.4 (0.4)     |
| 18:1 n-9 |      1168.5 (592.2)      |    37.8 (3.7)     |
| 20:1 n-9 |        8.5 (5.2)         |     0.3 (0.2)     |
| 22:1 n-9 |        1.0 (0.6)         |     0.0 (0.0)     |
| 24:1 n-9 |        2.2 (4.0)         |     0.1 (0.1)     |
| 14:0     |       62.4 (59.0)        |     1.8 (1.0)     |
| 16:0     |      868.0 (556.2)       |    26.6 (4.4)     |
| 18:0     |       113.6 (63.4)       |     3.7 (0.8)     |
| 20:0     |        1.9 (1.3)         |     0.1 (0.0)     |
| 22:0     |        1.5 (1.2)         |     0.1 (0.0)     |
| Total    |     3137.5 (1686.6)      |                   |

Table: Supplemental Table S  2: Concentration (nmol/mL) and relative percent (mol%) values of TGFA in PROMISE participants at the baseline visit (2004-2006).


| Fatty acid   | log(HOMA2-%S)          | log(ISI)               | log(IGI/IR)            | log(ISSI-2)           |
|:-------------|:-----------------------|:-----------------------|:-----------------------|:----------------------|
| **Totals**   |                        |                        |                        |                       |
| Clinical TAG | -23.4 (-28.9, -17.6)\* | -24.1 (-29.6, -18.1)\* | -18.2 (-25.3, -10.3)\* | -10.7 (-15.3, -6.0)\* |
| Total        | -22.2 (-27.5, -16.5)\* | -22.9 (-28.4, -17.0)\* | -16.4 (-23.3, -9.0)\*  | -9.8 (-14.1, -5.3)\*  |
| **nmol/mL**  |                        |                        |                        |                       |
| 14:0         | -19.1 (-23.7, -14.2)\* | -19.6 (-24.2, -14.6)\* | -11.3 (-17.3, -4.9)\*  | -6.9 (-10.5, -3.2)\*  |
| 16:0         | -23.0 (-28.3, -17.4)\* | -23.8 (-29.2, -18.0)\* | -17.2 (-24.0, -9.8)\*  | -10.2 (-14.5, -5.7)\* |
| 18:0         | -20.8 (-26.3, -15.0)\* | -21.3 (-27.1, -15.1)\* | -15.7 (-22.5, -8.3)\*  | -9.3 (-13.5, -4.9)\*  |
| 20:0         | -12.6 (-16.6, -8.4)\*  | -12.1 (-16.7, -7.2)\*  | -7.7 (-13.3, -1.8)\*   | -5.3 (-8.3, -2.2)\*   |
| 22:0         | -12.1 (-16.4, -7.5)\*  | -12.7 (-17.5, -7.8)\*  | -2.2 (-8.2, 4.1)       | -1.8 (-4.8, 1.2)      |
| 18:1 n-9     | -21.4 (-26.0, -16.6)\* | -22.0 (-26.8, -16.9)\* | -16.7 (-23.1, -9.8)\*  | -9.8 (-13.7, -5.7)\*  |
| 20:1 n-9     | -14.9 (-19.0, -10.5)\* | -14.2 (-18.9, -9.3)\*  | -13.2 (-19.7, -6.1)\*  | -7.2 (-10.9, -3.4)\*  |
| 22:1 n-9     | -14.0 (-19.6, -8.0)\*  | -12.3 (-18.5, -5.5)\*  | -12.0 (-16.6, -7.0)\*  | -6.3 (-9.0, -3.4)\*   |
| 24:1 n-9     | -4.3 (-8.5, 0.1)       | -6.4 (-10.9, -1.6)\*   | 3.5 (-2.5, 9.9)        | 1.8 (-1.3, 4.9)       |
| 14:1 n-7     | -14.9 (-19.5, -10.1)\* | -15.2 (-19.9, -10.3)\* | -9.4 (-15.1, -3.3)\*   | -5.5 (-8.7, -2.2)\*   |
| 16:1 n-7     | -19.2 (-24.3, -13.7)\* | -19.9 (-25.2, -14.3)\* | -15.0 (-21.9, -7.5)\*  | -8.6 (-12.8, -4.2)\*  |
| 18:1 n-7     | -22.2 (-26.0, -18.1)\* | -23.0 (-27.1, -18.6)\* | -17.0 (-22.7, -11.0)\* | -9.9 (-13.2, -6.4)\*  |
| 18:2 n-6     | -18.7 (-23.4, -13.7)\* | -19.1 (-23.9, -14.0)\* | -12.1 (-18.2, -5.6)\*  | -7.5 (-11.3, -3.5)\*  |
| 18:3 n-6     | -12.8 (-17.6, -7.7)\*  | -12.5 (-17.6, -7.1)\*  | -8.3 (-14.2, -2.0)\*   | -5.0 (-8.5, -1.3)\*   |
| 20:2 n-6     | -15.4 (-20.4, -10.1)\* | -15.8 (-20.9, -10.3)\* | -12.5 (-19.1, -5.3)\*  | -6.8 (-10.9, -2.5)\*  |
| 20:3 n-6     | -17.5 (-22.7, -12.0)\* | -18.1 (-23.3, -12.6)\* | -12.3 (-18.6, -5.4)\*  | -7.4 (-11.4, -3.3)\*  |
| 20:4 n-6     | -17.0 (-24.3, -9.0)\*  | -17.8 (-25.3, -9.6)\*  | -12.8 (-21.1, -3.6)\*  | -7.5 (-12.8, -1.8)\*  |
| 22:4 n-6     | -17.7 (-25.2, -9.5)\*  | -18.2 (-25.9, -9.9)\*  | -9.5 (-17.0, -1.3)\*   | -5.6 (-10.3, -0.7)\*  |
| 18:3 n-3     | -15.6 (-19.5, -11.6)\* | -16.6 (-20.7, -12.3)\* | -10.3 (-15.4, -4.8)\*  | -6.3 (-9.2, -3.4)\*   |
| 20:5 n-3     | -5.1 (-8.9, -1.1)\*    | -7.8 (-11.7, -3.8)\*   | -3.5 (-8.5, 1.7)       | -3.1 (-5.8, -0.2)\*   |
| 22:5 n-3     | -7.2 (-11.3, -2.8)\*   | -7.2 (-11.6, -2.6)\*   | -10.1 (-15.2, -4.7)\*  | -6.3 (-9.0, -3.5)\*   |
| 22:6 n-3     | -6.8 (-10.6, -2.8)\*   | -9.6 (-13.6, -5.5)\*   | -4.5 (-9.2, 0.4)       | -3.6 (-6.1, -0.9)\*   |
| **mol%**     |                        |                        |                        |                       |
| 14:0         | -14.2 (-18.0, -10.2)\* | -14.1 (-18.2, -9.8)\*  | -5.4 (-11.3, 1.0)      | -3.9 (-7.0, -0.7)\*   |
| 16:0         | -20.1 (-23.7, -16.3)\* | -20.7 (-24.5, -16.6)\* | -14.4 (-19.8, -8.6)\*  | -8.6 (-11.6, -5.6)\*  |
| 18:0         | 3.9 (-0.7, 8.8)        | 3.9 (-0.9, 9.1)        | 2.0 (-4.8, 9.4)        | 0.9 (-2.5, 4.4)       |
| 20:0         | 9.8 (2.8, 17.4)\*      | 10.6 (3.1, 18.5)\*     | 8.8 (1.6, 16.4)\*      | 3.8 (0.1, 7.7)        |
| 22:0         | 4.4 (-0.5, 9.5)        | 4.5 (-0.1, 9.4)        | 11.6 (5.7, 17.9)\*     | 5.7 (3.0, 8.5)\*      |
| 18:1 n-9     | 14.6 (9.1, 20.3)\*     | 15.3 (9.1, 21.9)\*     | 5.4 (-0.8, 12.1)       | 4.4 (1.2, 7.6)\*      |
| 20:1 n-9     | 7.4 (1.9, 13.1)\*      | 9.1 (3.8, 14.8)\*      | 2.8 (-4.3, 10.4)       | 2.3 (-1.6, 6.3)       |
| 22:1 n-9     | 10.0 (4.4, 15.8)\*     | 12.2 (6.3, 18.3)\*     | 6.1 (-1.0, 13.7)       | 4.0 (0.4, 7.7)\*      |
| 24:1 n-9     | 3.4 (-1.2, 8.3)        | 1.6 (-3.1, 6.6)        | 10.6 (4.1, 17.5)\*     | 4.9 (1.7, 8.2)\*      |
| 14:1 n-7     | -10.2 (-14.4, -5.7)\*  | -9.9 (-14.4, -5.2)\*   | -4.4 (-10.3, 1.8)      | -2.8 (-5.9, 0.4)      |
| 16:1 n-7     | -10.8 (-15.2, -6.2)\*  | -11.0 (-15.6, -6.2)\*  | -9.1 (-14.9, -2.9)\*   | -5.2 (-8.2, -2.0)\*   |
| 18:1 n-7     | 7.0 (1.5, 12.7)\*      | 7.2 (1.6, 13.1)\*      | 5.0 (-1.5, 11.9)       | 3.7 (0.4, 7.0)\*      |
| 18:2 n-6     | 12.8 (6.9, 19.0)\*     | 13.7 (7.5, 20.3)\*     | 11.4 (4.6, 18.7)\*     | 5.9 (2.5, 9.4)\*      |
| 18:3 n-6     | 8.9 (4.2, 13.8)\*      | 11.1 (6.2, 16.2)\*     | 9.1 (2.7, 16.0)\*      | 4.9 (1.8, 8.1)\*      |
| 20:2 n-6     | 21.6 (16.3, 27.1)\*    | 22.6 (16.9, 28.6)\*    | 11.3 (4.5, 18.7)\*     | 7.7 (4.4, 11.2)\*     |
| 20:3 n-6     | 4.3 (-0.1, 9.0)        | 4.1 (-0.6, 9.0)        | 2.9 (-2.2, 8.2)        | 1.3 (-1.3, 4.0)       |
| 20:4 n-6     | 10.1 (5.0, 15.4)\*     | 9.3 (3.4, 15.6)\*      | 4.8 (-1.4, 11.4)       | 3.0 (-0.1, 6.1)       |
| 22:4 n-6     | 1.8 (-2.8, 6.7)        | 2.2 (-2.4, 7.0)        | 7.9 (1.3, 14.9)\*      | 4.3 (1.3, 7.4)\*      |
| 18:3 n-3     | 5.5 (0.4, 10.9)\*      | 5.4 (-0.3, 11.4)       | 5.5 (-1.8, 13.2)       | 2.4 (-1.2, 6.1)       |
| 20:5 n-3     | 8.2 (1.7, 15.1)\*      | 4.9 (-1.8, 12.0)       | 7.3 (1.6, 13.3)\*      | 2.8 (-0.1, 5.8)       |
| 22:5 n-3     | 12.9 (7.3, 18.8)\*     | 12.6 (6.3, 19.2)\*     | 4.2 (-2.0, 10.9)       | 2.2 (-1.0, 5.5)       |
| 22:6 n-3     | 5.4 (0.1, 11.0)        | 2.3 (-3.0, 7.8)        | 5.3 (0.2, 10.7)        | 1.9 (-0.8, 4.7)       |

Table: Supplemental Table S  3: Raw estimates and confidence interval values for *time*-adjusted GEE models of the association of the TGFA (mol% and nmol/mL) and total clinically-measured TG with insulin sensitivity and beta-cell function outcomes using the 6 year longitudinal data from the PROMISE cohort. Estimates represent a percent difference in the outcome per SD increase in the FA. P-values were adjusted for the BH false discovery rate, with an asterisk (*) denoting a significant (p<0.05) association.



| Fatty acid   | log(HOMA2-%S)         | log(ISI)               | log(IGI/IR)          | log(ISSI-2)         |
|:-------------|:----------------------|:-----------------------|:---------------------|:--------------------|
| **Totals**   |                       |                        |                      |                     |
| Clinical TAG | -13.8 (-18.1, -9.3)\* | -14.8 (-19.3, -10.1)\* | -9.3 (-15.3, -2.9)\* | -4.9 (-8.3, -1.4)\* |
| Total        | -13.1 (-17.3, -8.7)\* | -14.3 (-18.7, -9.6)\*  | -7.9 (-13.5, -1.9)\* | -4.3 (-7.5, -1.1)\* |
| **nmol/mL**  |                       |                        |                      |                     |
| 14:0         | -11.2 (-14.8, -7.4)\* | -12.3 (-16.2, -8.3)\*  | -4.8 (-9.9, 0.6)     | -2.8 (-5.5, 0.0)    |
| 16:0         | -13.5 (-17.6, -9.1)\* | -14.8 (-19.2, -10.2)\* | -8.4 (-14.1, -2.4)\* | -4.6 (-7.7, -1.3)\* |
| 18:0         | -12.1 (-16.2, -7.7)\* | -13.1 (-17.7, -8.3)\*  | -8.3 (-14.0, -2.2)\* | -4.6 (-7.7, -1.4)\* |
| 20:0         | -6.3 (-9.7, -2.7)\*   | -6.6 (-10.7, -2.2)\*   | -4.0 (-9.4, 1.7)     | -3.0 (-5.7, -0.2)   |
| 22:0         | -7.8 (-11.6, -3.9)\*  | -8.0 (-12.3, -3.6)\*   | -1.2 (-6.7, 4.6)     | -1.3 (-3.8, 1.4)    |
| 18:1 n-9     | -12.4 (-16.3, -8.4)\* | -13.6 (-17.8, -9.2)\*  | -7.9 (-13.4, -2.1)\* | -4.2 (-7.2, -1.1)\* |
| 20:1 n-9     | -7.3 (-10.5, -3.9)\*  | -7.3 (-11.0, -3.5)\*   | -6.3 (-11.8, -0.4)   | -2.9 (-5.7, 0.1)    |
| 22:1 n-9     | -6.3 (-10.1, -2.3)\*  | -5.0 (-9.6, -0.2)      | -4.9 (-9.7, 0.1)     | -1.8 (-4.1, 0.7)    |
| 24:1 n-9     | -3.2 (-6.2, -0.1)     | -4.5 (-7.9, -0.9)\*    | 1.0 (-4.0, 6.2)      | 0.5 (-1.9, 3.0)     |
| 14:1 n-7     | -8.1 (-11.5, -4.6)\*  | -9.1 (-12.8, -5.4)\*   | -3.7 (-8.7, 1.6)     | -1.9 (-4.4, 0.7)    |
| 16:1 n-7     | -10.1 (-13.9, -6.1)\* | -11.2 (-15.3, -7.0)\*  | -6.1 (-11.7, -0.1)   | -2.9 (-5.8, 0.1)    |
| 18:1 n-7     | -12.2 (-16.0, -8.1)\* | -13.2 (-17.6, -8.6)\*  | -6.3 (-12.0, -0.2)   | -3.0 (-6.0, 0.0)    |
| 18:2 n-6     | -11.6 (-15.5, -7.6)\* | -12.3 (-16.3, -8.0)\*  | -6.0 (-11.4, -0.4)   | -3.8 (-6.7, -0.7)\* |
| 18:3 n-6     | -7.7 (-11.4, -3.8)\*  | -8.2 (-12.4, -3.8)\*   | -4.8 (-9.8, 0.5)     | -2.7 (-5.5, 0.2)    |
| 20:2 n-6     | -7.6 (-11.4, -3.6)\*  | -8.3 (-12.4, -4.0)\*   | -4.6 (-9.7, 0.7)     | -2.0 (-4.8, 0.9)    |
| 20:3 n-6     | -9.1 (-12.8, -5.3)\*  | -10.2 (-14.1, -6.2)\*  | -4.4 (-9.3, 0.7)     | -2.6 (-5.3, 0.2)    |
| 20:4 n-6     | -8.8 (-13.5, -3.9)\*  | -10.1 (-15.1, -4.8)\*  | -5.6 (-11.2, 0.3)    | -3.0 (-6.3, 0.5)    |
| 22:4 n-6     | -9.2 (-13.9, -4.2)\*  | -10.0 (-14.8, -4.9)\*  | -3.3 (-8.3, 2.1)     | -1.7 (-4.5, 1.3)    |
| 18:3 n-3     | -10.1 (-13.3, -6.9)\* | -11.1 (-14.5, -7.5)\*  | -6.0 (-10.9, -0.9)\* | -3.7 (-6.1, -1.2)\* |
| 20:5 n-3     | -2.6 (-5.8, 0.6)      | -5.4 (-8.8, -1.9)\*    | -0.4 (-4.8, 4.2)     | -1.3 (-3.5, 1.0)    |
| 22:5 n-3     | -2.3 (-5.8, 1.5)      | -3.2 (-7.2, 1.1)       | -1.7 (-6.9, 3.8)     | -1.7 (-4.3, 0.8)    |
| 22:6 n-3     | -4.2 (-7.6, -0.6)\*   | -6.8 (-10.4, -3.1)\*   | -0.3 (-4.4, 4.1)     | -1.3 (-3.5, 0.8)    |
| **mol%**     |                       |                        |                      |                     |
| 14:0         | -9.6 (-12.7, -6.4)\*  | -10.2 (-13.7, -6.6)\*  | -2.7 (-8.1, 3.0)     | -2.1 (-4.7, 0.7)    |
| 16:0         | -11.9 (-15.0, -8.6)\* | -12.8 (-16.4, -9.2)\*  | -7.1 (-12.2, -1.8)\* | -3.9 (-6.5, -1.3)\* |
| 18:0         | 2.5 (-1.1, 6.3)       | 2.1 (-1.8, 6.1)        | -1.6 (-7.5, 4.8)     | -1.2 (-4.0, 1.7)    |
| 20:0         | 6.6 (2.1, 11.2)\*     | 6.8 (1.9, 12.0)\*      | 3.2 (-2.6, 9.3)      | 0.9 (-2.2, 4.0)     |
| 22:0         | 1.3 (-2.0, 4.7)       | 2.0 (-1.5, 5.5)        | 4.3 (-1.9, 10.8)     | 1.6 (-1.0, 4.3)     |
| 18:1 n-9     | 8.8 (4.7, 13.1)\*     | 9.3 (4.4, 14.4)\*      | 3.9 (-1.7, 9.8)      | 3.2 (0.5, 6.0)\*    |
| 20:1 n-9     | 5.9 (1.9, 10.1)\*     | 6.9 (2.1, 12.0)\*      | 2.2 (-4.4, 9.2)      | 1.9 (-1.9, 5.9)     |
| 22:1 n-9     | 6.9 (3.0, 10.9)\*     | 8.7 (4.3, 13.3)\*      | 3.9 (-2.1, 10.4)     | 2.7 (-0.2, 5.7)     |
| 24:1 n-9     | 0.8 (-2.8, 4.5)       | 0.3 (-3.7, 4.4)        | 3.9 (-2.1, 10.2)     | 1.2 (-1.6, 4.1)     |
| 14:1 n-7     | -6.6 (-9.9, -3.2)\*   | -7.1 (-10.7, -3.3)\*   | -1.6 (-6.8, 4.0)     | -0.9 (-3.5, 1.8)    |
| 16:1 n-7     | -6.1 (-9.5, -2.6)\*   | -6.4 (-10.2, -2.5)\*   | -2.2 (-8.0, 4.0)     | -0.9 (-3.7, 2.0)    |
| 18:1 n-7     | 7.2 (3.1, 11.4)\*     | 8.1 (3.5, 12.8)\*      | 9.0 (2.9, 15.4)\*    | 5.7 (2.9, 8.6)\*    |
| 18:2 n-6     | 5.8 (1.5, 10.3)\*     | 7.5 (2.7, 12.6)\*      | 3.2 (-2.4, 9.0)      | 1.1 (-1.5, 3.8)     |
| 18:3 n-6     | 3.4 (-0.7, 7.6)       | 4.7 (0.2, 9.5)         | 2.1 (-3.6, 8.1)      | 1.1 (-1.7, 3.9)     |
| 20:2 n-6     | 14.4 (10.4, 18.6)\*   | 15.9 (11.2, 20.7)\*    | 6.9 (0.9, 13.1)\*    | 5.0 (2.1, 7.9)\*    |
| 20:3 n-6     | 4.3 (0.7, 8.0)\*      | 4.2 (0.2, 8.3)         | 2.6 (-2.0, 7.4)      | 1.1 (-1.2, 3.5)     |
| 20:4 n-6     | 6.5 (2.5, 10.7)\*     | 5.9 (1.1, 11.1)\*      | 1.3 (-3.9, 6.8)      | 1.0 (-1.5, 3.6)     |
| 22:4 n-6     | 2.4 (-1.1, 6.0)       | 2.9 (-0.8, 6.8)        | 4.2 (-1.7, 10.4)     | 2.4 (-0.2, 5.0)     |
| 18:3 n-3     | 1.0 (-2.7, 4.7)       | 1.5 (-2.7, 5.8)        | 0.3 (-5.4, 6.3)      | -0.6 (-3.3, 2.1)    |
| 20:5 n-3     | 4.2 (-0.1, 8.6)       | 1.3 (-3.4, 6.3)        | 3.8 (-0.5, 8.2)      | 0.8 (-1.4, 3.0)     |
| 22:5 n-3     | 8.7 (4.7, 12.8)\*     | 7.9 (3.1, 13.0)\*      | 4.3 (-0.7, 9.5)      | 1.7 (-0.8, 4.4)     |
| 22:6 n-3     | 2.4 (-1.1, 6.0)       | -0.2 (-4.0, 3.8)       | 3.3 (-0.7, 7.5)      | 0.6 (-1.6, 2.7)     |

Table: Supplemental Table S  4: Raw estimates and confidence interval values for *fully*-adjusted GEE models of the association of the TGFA (mol% and nmol/mL) and total clinically-measured TG with insulin sensitivity and beta-cell function outcomes using the 6 year longitudinal data from the PROMISE cohort. Variables controlled for were follow-up time, WC, baseline age, ethnicity, sex, ALT, physical activity, and total NEFA. Estimates represent a percent difference in the outcome per SD increase in the FA. P-values were adjusted for the BH false discovery rate, with an asterisk (*) denoting a significant (p<0.05) association.

# Supplemental Figures

![Supplemental Figure S  1: CONSORT diagram of PROMISE participants over the 3 visits.](../img/flowDiagramSample.png)

![Supplemental Figure S  2: Directed acyclic graphic output from the DAGitty online software for insulin sensitivity.](../img/dagitty-model-is.png)

![Supplemental Figure S  3: Directed acyclic graphic output from the DAGitty online software for beta-cell function.](../img/dagitty-model-bcf.png)

![Supplemental Figure S  4: Fully-adjusted (without waist size) GEE models of the association of the TGFA (mol% and nmol/mL) and total clinically-measured TG with insulin sensitivity and beta-cell function outcomes using the 6 year longitudinal data from the PROMISE cohort. Variables controlled for were follow-up time, baseline age, ethnicity, sex, ALT, physical activity, and total NEFA. X-axis values represent a percent difference in the outcome per SD increase in the FA. P-values were adjusted for the BH false discovery rate, with the largest dot representing a significant (p<0.05) association.](supplements_files/figure-docx/fig_gee_adj_nowaist-1.png)

![Supplemental Figure S  5: PLS loadings (or weights) for each of the TGFA. A larger loading indicates a higher contribution to the PLS component score.](supplements_files/figure-docx/fig_pls_loadings-1.png)



